Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.42 |
| ▸ | GLS | O94925 | 4/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.31 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553208 | 1.00 | MGLL (0.42) | MGLLGLSADORA2BENPP2ATXN2 | |
| SCHEMBL25326481 | 0.87 | MGLL (0.39) | MGLLADORA2B | |
| SCHEMBL30553145 | 0.87 | MGLL (0.39) | MGLLADORA2B | |
| SCHEMBL25324763 | 0.87 | MGLL (0.41) | MGLLENPP2ATXN2USP2CYP2D6 | |
| SCHEMBL30553182 | 0.85 | MGLL (0.39) | MGLLADORA2BENPP2ATXN2 | |
| SCHEMBL25326182 | 0.85 | MGLL (0.39) | MGLLADORA2BENPP2ATXN2 | |
| SCHEMBL30553215 | 0.85 | LPL (0.38) | MGLLGLSADORA2BENPP2ATXN2 | |
| SCHEMBL25325591 | 0.85 | LPL (0.38) | MGLLGLSADORA2BENPP2ATXN2 | |
| SCHEMBL25325486 | 0.84 | MGLL (0.39) | MGLLENPP2ATXN2USP2CYP2D6 | |
| SCHEMBL25327182 | 0.83 | MGLL (0.46) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | MGLL 3523/4885GLS 3938/4885ADORA2B 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.